A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

NCT01656642 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Melanoma

Interventions

DRUG: Atezolizumab
DRUG: Cobimetinib
DRUG: Vemurafenib

Sponsor

Genentech, Inc.